Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
Applied to very small human peripheral blood mononuclear cells, this work identifies up to 4000 proteins per cell, including key markers that distinguish monocytes, T cells, and activated lymphocytes within heterogeneous populations, underscoring that single-cell proteomics can now directly elucidate clinically relevan...
I. Hendriks, Sara C. Buch-Larsen, Martin Rykær et al.· Nature Communications· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.